The University of California San Diego (UCSD) School of Medicine received $4 million thanks to the California Institute for Regenerative Medicine (CIRM) to advance studies using new stem-cell-based treatments for multiple types of cancer and amyotrophic lateral sclerosis (ALS). Announced August 24, 2021, the funds are directed to three regenerative research initiatives, including 1) $1.4 million to develop a new chimeric antigen receptor (CAR-T) therapy for treating or drug-resistant malignancies such as ovarian cancer; 2) $1.1. million to develop new therapies for directing the migration of target-specific therapeutic stem cells; and 3) $1.2 million to develop a small molecule inhibitor that blocks the growth of cells that drive human pancreatic cancer and acute myeloid leukemia.
TrialSite provides a breakdown of the funder—CIRM, the principal investigators, and the research’s importance.
Regenerative Research Funding
The California Institute for Regenerative Medicine (CIRM) was born thanks to California voters approval of Proposition 71, known as the Research and Cures Initiative in 2004, when 59% of the voters in the Golden State authorized a law that, among other...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).